NanoSpot.ai on Tuesday announced an agreement with Opto, a provider of connected diagnostic tests, for the distribution of NanoSpot.ai’s SARS-CoV-2 Total Antibody Test in Greece.
The partnership resulted from a joint clinical study in Athens that evaluated NanoSpot.ai's artificial intelligence (AI)-enabled, agglutination-based testing platform.
Its SARS-CoV-2 Total Antibody Test leverages the agglutination-based method and an AI-enabled mobile application to provide antibody test results at point-of-care.
The approach has demonstrated 98% sensitivity and 100% specificity, and provides results in less than three minutes, NanoSpot.ai said.
The firm received the CE Mark for the test in May.